Top

Published in:

01-03-2022 | Colorectal Cancer | Original Research

Prognostic Significance of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Metastatic Colorectal Cancer

Authors: Gulcan Bulut, Zehra Narli Ozdemir

Published in: Journal of Gastrointestinal Cancer | Issue 1/2022

Abstract

There are many studies on the biomarkers for the prognosis in the treatment of metastatic colorectal cancer. Neutrophil-lymphocyte radio (NLR) and platelet-lymphocyte radio (PLR) are of interest with studies revealing the relationship between inflammatory biomarkers and cancer. Our study is a retrospective file study and the contribution of NLR and PLR to progression-free survival (PFS) and overall survival (OS) before first-line chemotherapy was investigated regardless of treatment. The cutoff values of NLR and PLR were determined using ROC curve analysis. NLR and PLR were divided into two groups according to the cut-off points. OS and PFS associated with NLR and PLR were performed by the Kaplan-Meier method. In our study, we could not demonstrate the prognostic potential of pre-treatment NLR and PLR in patients with mCRC treated with first-line chemotherapy. Our study showed that the use of these biomarkers in mCRC is limited.

Introduction

Material and Method

Our study is a retrospective file study and the contribution of NLR and PLR to progression-free survival (PFS) and overall survival (OS) before first-line chemotherapy was investigated regardless of treatment. The cutoff values of NLR and PLR were determined using ROC curve analysis. NLR and PLR were divided into two groups according to the cut-off points. OS and PFS associated with NLR and PLR were performed by the Kaplan-Meier method.

Result

In our study, we could not demonstrate the prognostic potential of pre-treatment NLR and PLR in patients with mCRC treated with first-linechemotherapy.

Conclusion

Our study showed that the use of these biomarkers in mCRC is limited.

Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–386. https://doi.org/10.1002/ijc.29210

Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii1–9. https://doi.org/10.1093/annonc/mdu260

Hamers PAH, Elferink MAG, Stellato RK, et al. Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data. Int J Cancer. 2020;15;148(2):296–306. https://doi.org/10.1002/ijc.33200

Stein A, Bokemeyer C. How to select the optimal treatment for first line metastatic colorectal cancer. World J Gastroenterol. 2014;20:899–907. https://doi.org/10.3748/wjg.v20.i4.899.CrossRefPubMedPubMedCentral

De Divitiis C, Nasti G, Montano M, et al. Prognostic and predictive response factors in colorectal cancer patients: between hope and reality. World J Gastroenterol. 2014;20:15049–59. https://doi.org/10.3748/wjg.v20.i41.15049

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7. https://doi.org/10.1038/nature01322.CrossRefPubMedPubMedCentral

Lu H, Ou yang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006;4:221–33. https://doi.org/10.1158/1541-7786.MCR-05-0261

Tartour E, Zitvogel L. Lung cancer: potential targets for immunotherapy. Lancet Respir Med. 2013;1:551–63. https://doi.org/10.1016/S2213-2600(13)70159-0.CrossRefPubMed

Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res. 2013;73(8):2381 2388. https://doi.org/10.1158/0008-5472.CAN-12-3932

10.

Shang K, Bai YP, Wang C, et al. Crucial involvement of tumor-associated neutrophils in the regulation of chronic colitis-associated carcinogenesis in mice.PLoS One. 2012;7(12):e51848. https://doi.org/10.1371/journal.pone.0051848

11.

Sagiv JY, Michaeli J, Assi S, et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 2015;10(4):562–73. https://doi.org/10.1016/j.celrep.2014.12.039

12.

Sionov RV, Fridlender ZG, Granot Z. The multifaceted roles neutrophils play in the tumor microenvironment. Cancer Microenviron. 2015;8(3):125–58. https://doi.org/10.1007/s12307-014-0147-5.CrossRefPubMed

13.

Pilatova K, Zdrazilova-Dubska L, Klement GL The role of platelets in tumour growth. Klin Onkol. 2012;25(Suppl 2):2S50–7.

14.

Malietzis G, Giacometti M, Kennedy RH, et al. The emerging role of neutrophil to lymphocyte ratio in determining colorectal cancer treatment outcomes: a systematic review and meta-analysis. Ann Surg Oncol. 2014;21:3938–46. https://doi.org/10.1245/s10434-014-3815-2

15.

Feng JF, Huang Y, Chen QX. The combination of platelet count and neutrophil lymphocyte ratio is a predictive factor in patients with esophageal squamous cell carcinoma. Transl Oncol. 2014;7:632–7. https://doi.org/10.1016/j.tranon.2014.07.009.CrossRefPubMedPubMedCentral

16.

Galizia G, Lieto E, Zamboli A, et al. Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: a propensity score-matched analysis. Surgery. 2015;158:112–20. https://doi.org/10.1016/j.surg.2015.02.006

17.

Shin JS, Suh KW, Oh SY. Preoperative neutrophil to lymphocyte ratio predicts survival in patients with T1–2N0 colorectal cancer. J Surg Oncol. 2015;112:654–7 https://doi.org/10.1002/jso.24061

18.

Krauthamer M, Rouvinov K, Ariad S, et al. A study of inflammation-based predictors of tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Oncology. 2013;85:27–32. https://doi.org/10.1159/000348385

19.

Kim IY, You SH, Kim YW. Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer. BMC Surg. 2014;14:94. https://doi.org/10.1186/1471-2482-14-94.CrossRefPubMedPubMedCentral

20.

Pichler M, Absenger G, Stotz M, et al. The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients. Am J Surg. 2014;208:210–4. https://doi.org/10.1016/j.amjsurg.2013.10.030.CrossRefPubMed

21.

Zhang Y, Jiang C, Li J, Sun J, Qu X. Prognostic significance of preoperative neutrophil/lymphocyte ratio and nplatelet/lymphocyte ratio in patients with gall bladder carcinoma. Clin Transl Oncol. 2015;17:810–8. https://doi.org/10.1097/MD.0000000000014550.CrossRefPubMed

22.

Bozkurt O, Karaca H, Berk V, et al. Predicting the role of the pretreatment neutrophil to lymphocyte ratio in the survival of early triple- negative breast cancer patients. JBUON. 2015;20:1432–9.PubMed

23.

Roxburgh CSD, McMillan D. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6:149–63. https://doi.org/10.2217/fon.09.136.CrossRefPubMed

24.

Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104:1288–95. https://doi.org/10.1038/bjc.2011.100.CrossRefPubMedPubMedCentral

25.

Dell’Aquila E, Cremolini C, et al. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the tribe study by gono. Ann Oncol. 2018;29:924–30. https://doi.org/10.1093/annonc/mdy004.CrossRefPubMed

26.

Matsuda A, Yamada T, Matsuda S, et al. Prognostic role of the platelet-to-lymphocyte ratio for patients with metastatic colorectal cancer treated with aflibercept. In Vivo. 2020;34(5): 2667–2673. https://doi.org/10.21873/invivo.12086

27.

Dogan E, Bozkurt O, Sakalar T, et al. Impact of neutrophil-lymphocyte and platelet-lymphocyte ratio on antiEGFR and bevacizumab efficacy in metastatic colorectal cancer. JBUON 2019;24(5): 1861–1869

28.

Nogueira-Costa G, Fernandes I, Gameiro R, et al. Prognostic utility of neutrophil-to-lymphocyte ratio in patients with metastatic colorectal cancer treated using different modalities. Curr Oncol. 2020;27(5): 237–243. https://doi.org/10.3747/co.27.6573

29.

Yang J, Guo X, Wang M, Ma X, Ye X, Lin P. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS. Sci Rep. 2017;7:17166. https://doi.org/10.1038/s41598-017-17130-6.CrossRefPubMedPubMedCentral

Title: Prognostic Significance of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Metastatic Colorectal Cancer
Authors: Gulcan Bulut
Zehra Narli Ozdemir
Publication date: 01-03-2022
Publisher: Springer US
Keywords: Colorectal Cancer
Colorectal Cancer
Cytostatic Therapy
Published in: Journal of Gastrointestinal Cancer / Issue 1/2022
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-021-00616-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Material and Method

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

Incidence, Survival and Prognostic Factors of Oesophagogastric Cancer

Correction to: Investigating Trends of Incidence Rates of Esophageal Cancer Divided by Squamous Cell Carcinoma and Adenocarcinoma in Southern Iran: a 10-Year Experience

Port-Site Metastases in Incidentally Detected Carcinoma Gall Bladder: Role of 18F-FDG PET/CT and Patient Outcome

Disaggregating Data on Pacific Islander Gastric Cancer Patients Reveals Survival Disparity

Prognostic Factors for Survival in Transverse Colon Cancers

Could the Inflammatory Prognostic Index Predict the Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer?

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage